With this respect, in the attempt to find new molecules targeting NRF2, Chen et al. have shown that the topoisomerase inhibitor Camptothecin could markedly suppress NRF2 expression and downstream target gene transactivation in different cancer cell lines such as HepG2, SMMC-7721, and A549. This evidence concerns the gene NFE2L2 and cancer.